Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Get in-depth healthcare industry analysis with the unparalleled resources at Informa Pharma Intelligence.
Follow the evolution of the Zolgensma story and examine its possible implications for the future of product approval procedures.
Your free Pink Sheet pack includes:
The 2019 Titan of Pharma infographic is a snapshot of the industry’s top leaders and the businesses they oversee, including:
Pharma R&D Annual Review 2019 is based on the stats and data from Pharmaprojects, part of Informa’s Citeline family of intelligence solutions. Authored for the 27th time by Ian Lloyd, Senior Director, Pharmaprojects, this whitepaper contains the whole nine yards:
The ball is in your court: tap into the industry expertise and experience of Ian Lloyd, backed by the rock-solid data from Pharmaprojects download Pharma R&D Annual Review 2019 from Citeline, today.
Listen to our special Spotify playlist while you read. We hope you enjoy this tongue-in-cheek collection of songs, specially curated as the perfect accompaniment to the Pharma R&D Annual Review 2019.
Biomedtracker, Datamonitor Healthcare
The Pharma Intelligence analyst team will be covering the 2021 ASCO virtual meeting from June 4-8, 2021.
Medtech Insight
Industry wants to see the number of products for which electronic IFU are permitted to be expanded. But there is a strong lobby pushing for paper IFU to still be made available.
Generics Bulletin
Celltrion has pushed into another new market with its Remsima SC subcutaneous version of infliximab, launching the innovative biosimilar in Canada.
Pink Sheet
Biogen/Eisai Alzheimer’s drug wins agency nod on basis of amyloid plaque reduction, a surprising use of the accelerated approval pathway that was not considered by an FDA advisory committee; approval raises feasibility questions about confirmatory trial and daunting prospect of market withdrawal if studies fail to verify clinical benefit.
Medtech Insight
Updates to the EU Medical Devices Regulation are just weeks away from becoming a reality for manufacturers and suppliers. Medtech Insight delivers expert insights into the latest developments and what they could mean for your business.
Topic Medtech
Scrip
In this audio interview, the head of IQVIA Biotech (Japan-Asia Pacific) talks to Scrip on a range of aspects around digitalization and virtualization of clinical research in the region, including sharply reduced site contracting timelines. He also touches on the digital product launch efforts that are currently a reality in several markets.
Medtech Insight
Medtronic said it will launch the SenSight DBS in the US after winning FDA approval. The total DBS market is expected to exceed $1bn by 2024, according to Meddevicetracker.
Citeline
The goal of our second Clinical Trials & the COVID-19 Vaccine Pulse Report is to uncover who is still hesitant to take a vaccine, and what public health experts from pharma to the U.S. government can do to turn the tide.
Topic Coronavirus Clinical Trials
Datamonitor Healthcare
One hundred billion dollars. That is the combined revenue of the top 10 pharmaceuticals in 2020, marking the first year in which this threshold has been crossed.
Topic Drug Review Drug Pricing
In Vivo
Gain insights into managing unexpected events, effectively communicating change, executing crisis management plans, and more. Industry experts share their insights into innovative ways to integrate teams after M&A, manage D&I initiatives, and build strong leadership for a changing workforce.
Topic Leadership
HBW Insight
Senate bill provision allowing FDA to develop unique labeling and packaging for cannabinoid supplements and foods is unnecessary, as the products should following existing labeling regulations, says CRN chief Steve Mister.
Pink Sheet, Scrip
Tap into expert coverage of the complex world of drug pricing with insights from analysts at Scrip and Pink Sheet. This eBook includes vital information about issues affecting drug pricing for the US, EU, and other global markets, including patient access, regulatory issues, commercial challenges, value-based pricing, and more.
Topic Drug Pricing
Scrip
Results will be important in fight against new variants, for second-generation vaccines and AstraZeneca’s controversy-hit jab.
Scrip
12 Jun 2021
Scrip
12 Jun 2021
Scrip
12 Jun 2021
Pink Sheet
11 Jun 2021
Pink Sheet
11 Jun 2021
Medtech Insight
11 Jun 2021
Pink Sheet
11 Jun 2021
Generics Bulletin
11 Jun 2021
Pink Sheet
11 Jun 2021
HBW Insight
11 Jun 2021
Scrip
11 Jun 2021
Medtech Insight
11 Jun 2021
Medtech Insight
11 Jun 2021
Generics Bulletin
11 Jun 2021
Generics Bulletin
11 Jun 2021
Request a live demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
